Skip to main content Skip to section navigation Skip to footer
Bioscience Obesity
Our Company Pipeline Media & Investors Contact
Skye Bioscience, Inc. IR Overview
  • Investors
  • News
  • Company Info
    • Highlights
    • Corporate Presentation
    • IR Calendar/Webcasts
    • Executive Team
    • Email Alerts
    • Contacts
    • FAQ
  • Spotlight
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Analyst Coverage
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
  • Back to CorporateSite.com

News Releases

Investors

Investors

  • Investors
  • News
  • Company Info
    • Highlights
    • Corporate Presentation
    • IR Calendar/Webcasts
    • Executive Team
    • Email Alerts
    • Contacts
    • FAQ
  • Spotlight
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Analyst Coverage
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
May 8, 2025 4:01 pm EDT
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 7, 2025 7:00 am EDT
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Apr 29, 2025 7:00 am EDT
Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 25, 2025 8:06 pm EDT
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025 7:00 am EDT
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 14, 2025 7:00 am EDT
Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Mar 20, 2025 4:01 pm EDT
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 14, 2025 7:00 am EDT
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Feb 27, 2025 6:00 pm EST
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2025 7:00 am EST
Skye Bioscience to Participate in SXSW Session on Obesity

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • account_treeSitemap
11250 El Camino Real, Suite 100
San Diego, CA 92130
info@skyebioscience.com
Company
Our Company Careers Investors Contact
Product
Obesity
Media
News
© 2025 Skye Bioscience.
All Rights Reserved.
Terms of use Privacy Policy
Facebook Twitter LinkedIn